Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG)
CAPS Rating:
The Company is seeking to develop and commercialize new diagnostic and therapeutic products based on a recently discovered group of genes known as microRNAs.
The Company is seeking to develop and commercialize new diagnostic and therapeutic products based on a recently discovered group of genes known as microRNAs.
Recs
Swing trade after another spike. Trading stock. Long term value very questionable, short term, well above valid metrics. I did call this one up a few times. New shares issued around $5.00 helped set a floor, but may add liquidity, slowing these erratic, high beta runs. Trade between $5.30 and $6.00. Hit it on either side. May get caught at any given point. NOTE 3 month "estimate". Most likely 7-10 days and back out before this catches a low float, short covering, temporary, but painful, speculating updraft.